Home › Companies › G1 THERAPEUTICS INC. › 2023-2024
At G1 THERAPEUTICS INC.'s shareholder meeting held June 13, 2024, in the 2023-2024 proxy season, 79 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 253 separate fund positions. On the most widely held item on that ballot — An advisory (non-binding) vote to approve executive compensation — G1 THERAPEUTICS INC.'s filing reports the proposal as approved, with 84% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: G1 THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and G1 THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 13, 2024: 5 items on G1 THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024: 2 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore G1 THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are G1 THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Cynthia L. Flowers | 15,551,849 | -- | -- | 4,429,769 | 16,596,262 | 78% | Not verified | — |
| Elect Director: John E. Bailey, Jr. | 19,236,332 | -- | -- | 745,286 | 16,596,262 | 96% | Not verified | — |
| 2. Advisory Vote on the Compensation of Our Named Executive Officers | 16,706,545 | 3,182,510 | 92,563 | -- | 16,596,262 | 84% | Approved | — |
| 3. Ratification of Appointment of Independent Registered Public Accounting Firm | 35,199,177 | 1,155,216 | 223,487 | -- | -- | 97% | Approved | — |
| 4. Proposal to amend and restate the Company's Certificate of Incorporation to include officer exculpation | 18,803,243 | 1,138,569 | 39,806 | -- | 16,596,262 | 94% | Not verified | — |
Source: G1 THERAPEUTICS INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.
Each item below shows how the 79 asset managers that disclosed a G1 THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: The election of two Class I directors: Cynthia L. Flowers
G1 THERAPEUTICS INC.’s own tally for this item (“Elect Director: Cynthia L. Flowers”): 15,551,849 for, 4,429,769 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 2,446,965 for, 722,421 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,069,685 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 423,869 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 237,243 | Withhold |
| Fidelity | 209,256 | 0 | 0 | 300 | For |
| NEEDHAM FUNDS INC | 105,000 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 34,648 | Withhold |
| Charles Schwab | 21,516 | 0 | 0 | 0 | For |
| T. Rowe Price | 17,755 | 0 | 0 | 0 | For |
| BlackRock | 15,655 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 12,064 | Withhold |
| Equitable | 8,097 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 6,417 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 5,400 | Withhold |
| Allianz | 0 | 0 | 0 | 1,432 | Withhold |
| John Hancock | 0 | 0 | 0 | 826 | Withhold |
| Nationwide | 0 | 0 | 0 | 221 | Withhold |
| Dimensional | 0 | 0 | 0 | 1 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 1 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: The election of two Class I directors: John E. Bailey, Jr.
G1 THERAPEUTICS INC.’s own tally for this item (“Elect Director: John E. Bailey, Jr.”): 19,236,332 for, 745,286 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 3,149,472 for, 19,914 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,069,685 | 0 | 0 | 0 | For |
| Aberdeen | 423,869 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 237,243 | 0 | 0 | 0 | For |
| Fidelity | 209,556 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 105,000 | 0 | 0 | 0 | For |
| American Century | 34,648 | 0 | 0 | 0 | For |
| Charles Schwab | 21,516 | 0 | 0 | 0 | For |
| T. Rowe Price | 17,755 | 0 | 0 | 0 | For |
| BlackRock | 15,655 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 12,064 | Withhold |
| Equitable | 8,097 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 6,417 | Withhold |
| Blackstone Alternative Investment Funds | 5,400 | 0 | 0 | 0 | For |
| Allianz | 0 | 0 | 0 | 1,432 | Withhold |
| John Hancock | 826 | 0 | 0 | 0 | For |
| Nationwide | 221 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 1 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Approval of the amendment and restatement of G1 Therapeutics, Inc.'s Certificate of Incorporation to reflect new Delaware law on provisions regarding officer exculpation
G1 THERAPEUTICS INC.’s own tally for this item (“4. Proposal to amend and restate the Company's Certificate of Incorporation to include officer exculpation”): 18,803,243 for, 1,138,569 against, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 3,169,386 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,069,685 | 0 | 0 | 0 | For |
| Aberdeen | 423,869 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 237,243 | 0 | 0 | 0 | For |
| Fidelity | 209,556 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 105,000 | 0 | 0 | 0 | For |
| American Century | 34,648 | 0 | 0 | 0 | For |
| Charles Schwab | 21,516 | 0 | 0 | 0 | For |
| T. Rowe Price | 17,755 | 0 | 0 | 0 | For |
| BlackRock | 15,655 | 0 | 0 | 0 | For |
| Jackson National | 12,064 | 0 | 0 | 0 | For |
| Equitable | 8,097 | 0 | 0 | 0 | For |
| Lincoln Financial | 6,417 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 5,400 | 0 | 0 | 0 | For |
| Allianz | 1,432 | 0 | 0 | 0 | For |
| John Hancock | 826 | 0 | 0 | 0 | For |
| Nationwide | 221 | 0 | 0 | 0 | For |
| Dimensional | 1 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
84% Approved · of votes cast
Description as filed by funds: An advisory (non-binding) vote to approve executive compensation
G1 THERAPEUTICS INC.’s own tally for this item (“2. Advisory Vote on the Compensation of Our Named Executive Officers”): 16,706,545 for, 3,182,510 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(2) approved, on a non-binding, advisory basis, compensation awarded or paid to the Company's named executive officers for the fiscal year of 2023 (the "Advisory Vote on the Compensation of Our Named Executive Officers")”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,069,685 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 423,869 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 237,243 | 0 | 0 | 0 | For |
| Fidelity | 209,556 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 0 | 105,000 | 0 | 0 | Against |
| American Century | 34,648 | 0 | 0 | 0 | For |
| Charles Schwab | 21,516 | 0 | 0 | 0 | For |
| T. Rowe Price | 17,755 | 0 | 0 | 0 | For |
| BlackRock | 15,655 | 0 | 0 | 0 | For |
| Jackson National | 12,064 | 0 | 0 | 0 | For |
| Equitable | 8,097 | 0 | 0 | 0 | For |
| Lincoln Financial | 6,417 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 5,400 | 0 | 0 | 0 | For |
| Allianz | 1,432 | 0 | 0 | 0 | For |
| John Hancock | 826 | 0 | 0 | 0 | For |
| Nationwide | 221 | 0 | 0 | 0 | For |
| Dimensional | 1 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1 | 0 | 0 | 0 | For |
Fund voting reports, all 18 managers: 2,640,517 for, 528,869 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| DE Shaw | 711,859 | 0 | 0 | 0 | For |
| BlackRock | 519,213 | 0 | 0 | 0 | For |
| Renaissance | 462,059 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 423,869 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 397,229 | 0 | 0 | 0 | For |
| Goldman Sachs | 387,077 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 380,000 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 377,858 | 0 | 0 | 0 | For |
| Point72 | 375,172 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 254,005 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 251,000 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 237,243 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 226,861 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 202,339 | 0 | 0 | 0 | For |
| Two Sigma | 197,139 | 0 | 0 | 0 | For |
| Northern Trust | 101,292 | 0 | 0 | 0 | For |
| FinTrust Capital Advisors, LLC | 100,780 | 0 | 0 | 0 | For |
| FRANKLIN STREET ADVISORS INC /NC | 83,400 | 0 | 0 | 0 | For |
| Birchview Capital, LP | 80,000 | 0 | 0 | 0 | For |
| NEEDHAM INVESTMENT MANAGEMENT LLC | 75,000 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 68,883 | 0 | 0 | 0 | For |
| Fidelity | 50,778 | 0 | 0 | 0 | For |
| Beacon Pointe Advisors, LLC | 43,700 | 0 | 0 | 0 | For |
| CHOREO, LLC | 35,234 | 0 | 0 | 0 | For |
| American Century | 34,648 | 0 | 0 | 0 | For |
Institutional-manager reports, all 68 managers: 5,908,792 for, 424,266 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2024
G1 THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Public Accounting Firm”): 35,199,177 for, 1,155,216 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 (the "Ratification of Appointment of Independent Registered Public Accounting Firm")”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 3,169,386 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,069,685 | 0 | 0 | 0 | For |
| Aberdeen | 423,869 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 237,243 | 0 | 0 | 0 | For |
| Fidelity | 209,556 | 0 | 0 | 0 | For |
| NEEDHAM FUNDS INC | 105,000 | 0 | 0 | 0 | For |
| American Century | 34,648 | 0 | 0 | 0 | For |
| Charles Schwab | 21,516 | 0 | 0 | 0 | For |
| T. Rowe Price | 17,755 | 0 | 0 | 0 | For |
| BlackRock | 15,655 | 0 | 0 | 0 | For |
| Jackson National | 12,064 | 0 | 0 | 0 | For |
| Equitable | 8,097 | 0 | 0 | 0 | For |
| Lincoln Financial | 6,417 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 5,400 | 0 | 0 | 0 | For |
| Allianz | 1,432 | 0 | 0 | 0 | For |
| John Hancock | 826 | 0 | 0 | 0 | For |
| Nationwide | 221 | 0 | 0 | 0 | For |
| Dimensional | 1 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 52,281,391 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.96% |
| 2 | Aberdeen | 0.81% |
| 3 | BRIDGEWAY FUNDS INC | 0.45% |
| 4 | Fidelity | 0.40% |
| 5 | NEEDHAM FUNDS INC | 0.20% |
| 6 | American Century | 0.07% |
| 7 | Charles Schwab | 0.04% |
| 8 | T. Rowe Price | 0.03% |
| 9 | BlackRock | 0.03% |
| 10 | Jackson National | 0.02% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | DE Shaw | 1.36% |
| 2 | BlackRock | 0.99% |
| 3 | Renaissance | 0.88% |
| 4 | Aberdeen | 0.81% |
| 5 | Connor, Clark & Lunn Investment Management Ltd. | 0.76% |
| 6 | Goldman Sachs | 0.74% |
| 7 | PNC BANK, NATIONAL ASSOCIATION | 0.73% |
| 8 | JACOBS LEVY EQUITY MANAGEMENT, INC | 0.72% |
| 9 | Point72 | 0.72% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 0.49% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Renaissance Technologies | 1.73% | 13F |
| D.E. Shaw | 1.50% | 13F |
| Geode Capital | 0.97% | 13F |
| Millennium Management | 0.85% | 13F |
| Two Sigma | 0.64% | 13F |
| State Street | 0.31% | 13F |
| Northern Trust | 0.24% | 13F |
| Citadel Advisors | 0.23% | 13F |
| Dimensional Fund Advisors | 0.15% | 13F |
| Charles Schwab | 0.04% | 13F |
Percentages above are of 52,281,391 shares outstanding, as reported by G1 THERAPEUTICS INC. on its Form 10-Q dated April 26, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from G1 THERAPEUTICS INC.’s 10-Q dated April 26, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
G1 THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “G1 THERAPEUTICS INC. 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/g1-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.